Bravi D, Davis T L, Mouradian M M, Chase T N
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Mov Disord. 1993 Apr;8(2):195-7. doi: 10.1002/mds.870080214.
The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co-administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa-induced dyskinesias.
在可控条件下，对帕金森病患者评估了部分多巴胺激动剂EMD 49980的运动效应。EMD 49980单药治疗使帕金森病症状有轻度改善，但与左旋多巴联合使用时，对异动症或多巴胺前体的抗帕金森病效应无显著影响。这些结果表明，EMD 49980发挥了净弱多巴胺激动剂效应，但未能改善左旋多巴诱发的异动症。
